GPNMB and glaucoma: To determine if PLX5622 treatment altered glaucoma-relevant phenotypes, D2 and normotensive D2-Gpnmb+ controls (Howell et al., 2007) were provided either the PLX5622 diet or control diet from 9.5 to 12 mos.